Stockscreener 앱 받기
1.66
5.14%
-0.09
전일 마감가:
$1.75
열려 있는:
$1.79
하루 거래량:
9.78M
Relative Volume:
1.94
시가총액:
$247.68M
수익:
-
순이익/손실:
$-14.07M
주가수익비율:
-0.1187
EPS:
-13.99
순현금흐름:
$-12.56M
1주 성능:
-16.58%
1개월 성능:
-3.49%
6개월 성능:
+121.04%
1년 성능:
+0.00%
1일 변동 폭
$1.635
$1.8076
1주일 범위
$1.635
$2.01
52주 변동 폭
$0.53
$2.64
Palisade Bio Inc Stock (PALI) Company Profile
명칭
Palisade Bio Inc
전화
(858) 704-4900
주소
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
PALI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.66 | 261.11M | 0 | -14.07M | -12.56M | -13.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 개시 | B. Riley Securities | Buy |
| 2025-12-29 | 개시 | Piper Sandler | Overweight |
Palisade Bio Inc 주식(PALI)의 최신 뉴스
Aug Retail: Should I invest in Palisade Bio Inc before earningsInsider Selling & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Activity Recap: Can Palisade Bio Inc beat the S P 500Weekly Profit Summary & AI Based Buy and Sell Signals - baoquankhu1.vn
Palisade Bio announces two abstracts selected for poster presentations at leading global inflammatory bowel disease conferences - marketscreener.com
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences - Weekly Voice
Ulcerative colitis drug PALI-2108 to be spotlighted at two IBD meetings - Stock Titan
Palisade Bio (PALI) Price Target Increased by 12.86% to 13.43 - Nasdaq
Palisade Bio director Williams buys $9,400 in shares By Investing.com - Investing.com South Africa
Palisade Bio director Williams buys $9,400 in shares - Investing.com
Sentiment Watch: Can Palisade Bio Inc beat the S P 500July 2025 Drop Watch & AI Enhanced Execution Alerts - baoquankhu1.vn
Palisade Bio (PALI) soars 5% ahead of clinical trial results - MSN
Short Covering: Is Palisade Bio Inc stock a dividend growth opportunity2025 Trading Volume Trends & Consistent Profit Focused Trading Strategies - moha.gov.vn
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Palisade Bio (PALI) upgraded to buy: Here's what you should know - MSN
PALI: B. Riley Securities Initiates Coverage with 'Buy' Rating | - GuruFocus
B. Riley Initiates Palisade Bio at Buy With $7 Price Target - marketscreener.com
B.Riley initiates coverage on Palisade Bio stock with Buy rating By Investing.com - Investing.com Nigeria
B.Riley initiates coverage on Palisade Bio stock with Buy rating - Investing.com Nigeria
How Palisade Bio Inc. (7NS0) stock reacts to Fed tighteningShort Setup & Consistent Profit Trading Strategies - Улправда
Can Palisade Bio Inc. stock deliver consistent earnings growthTrade Risk Report & Expert Approved Momentum Ideas - Улправда
What is the fair value of Palisade Bio Inc. stock nowEarnings Growth Summary & Verified Momentum Stock Ideas - Улправда
Crohn’s & Colitis Foundation invests up to $500,000 in Palisade Bio By Investing.com - Investing.com Nigeria
How currency fluctuations impact Palisade Bio Inc. stockEx-Dividend Date Alerts & Low Entry Cost Investment - Улправда
Exit Recap: Will Palisade Bio Inc stock attract more institutional investors2025 AllTime Highs & High Conviction Buy Zone Alerts - Bộ Nội Vụ
Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108 - The Manila Times
Palisade Bio Announces Strategic Investment from Crohn's & Colitis Foundation to Support Development of PALI-2108 for Ulcerative Colitis and Crohn's Disease - Quiver Quantitative
Palisade Bio Announces Strategic Equity Investment from the - GlobeNewswire
Crohn’s & Colitis Foundation backs new gut-targeted drug for severe IBD - Stock Titan
Will Palisade Bio Inc. stock benefit from sector rotationStability vs Neutral Overview & HOKA buying tips before checkout - ulpravda.ru
Palisade Bio, Inc. (NASDAQ:PALI) Receives $20.50 Average Price Target from Analysts - Defense World
Wall Street Zen Upgrades Palisade Bio (NASDAQ:PALI) to "Hold" - MarketBeat
Risk Report: What is the fair value of Palisade Bio Inc stock now2025 Major Catalysts & Intraday High Probability Setup Alerts - moha.gov.vn
Analysts Are Bullish on These Healthcare Stocks: Palisade Bio (PALI), Centessa Pharmaceuticals (CNTA) - The Globe and Mail
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Palisade Bio (NASDAQ:PALI) Stock Rating Upgraded by Clear Str - MarketBeat
Piper Sandler Initiates Coverage on Palisade Bio (NASDAQ:PALI) - Defense World
9,119,152 Common Stock of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Certain Stock Options of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Certain Warrants of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Palisade Bio receives patent approval in Japan for IBD drug PALI-2108 - Investing.com Nigeria
Palisade Bio Says Japan Grants Patent for Composition of PALI-2108 - MarketScreener
Palisade Bio receives patent approval in Japan for IBD drug PALI-2108 By Investing.com - Investing.com South Africa
New gut-targeted drug gains key patent in Japan for severe bowel disease - Stock Titan
Palisade Bio (NASDAQ:PALI) Upgraded at Piper Sandler - MarketBeat
Palisade Bio stock initiated with Buy rating at Clear Street on IBD drug potential - Investing.com
Palisade Bio Appoints New VP to Drive Further Growth - StocksToTrade
DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday - Benzinga
PALI’s Strategic Move: What’s Next? - timothysykes.com
Piper Sandler initiates Palisade Bio stock with Overweight rating on IBD drug By Investing.com - Investing.com Nigeria
Piper Sandler initiates Palisade Bio stock with Overweight rating on IBD drug - Investing.com
Palisade Bio (PALI) Soars 5% Ahead of Clinical Trial Results - Finviz
Palisade Bio Inc (PALI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):